FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2041820493> ?p ?o ?g. }

• W2041820493 endingPage "165" @default.
• W2041820493 startingPage "143" @default.
• W2041820493 abstract "It has been roughly 25 years since the threat posed by human immunodeficiency virus type 1 (HIV-1) became widely known. The cumulative death toll from HIV/AIDS is now greater than 25 million. There are approximately 33 million people living worldwide with this disease, of whom about 68% (22.5 million) live in sub-Saharan Africa (http://www.avert.org/worldstats.htm). A number of antiretroviral (ARV) drugs have been approved for treatment of HIV/AIDS. Inhibitors of HIV reverse transcriptase (RTIs) include the nucleoside/nucleotide drugs zidovudine, lamivudine, abacavir, didanosine, stavudine, emtricitabine and tenofovir disoproxil fumarate. Non-nucleoside RTIs include nevirapine, efavirenz and etravirine. Inhibitors of HIV protease (PIs) include saquinavir, ritonavir, lopinavir, nelfinavir, indinavir, fosamprenavir and atazanavir. Enfuvirtide inhibits the HIV fusion protein. The CCR5 chemokine antagonist maraviroc and the integrase inhibitor raltegravir were very recently approved by the US FDA. Fixed-dose combinations (FDCs) have been formulated to increase tolerability, convenience and compliance. First-line drug combinations are offered to treatment-naive patients, while second-line drugs are reserved for those who no longer respond adequately to first-line therapy. In developing countries a modest but increasing fraction of those infected have access to ARVs. The Clinton HIV/AIDS Initiative estimates that 2.4 million of the nearly 8 million individuals needing treatment in developing nations have access to some drugs. First-line FDCs used in resource-poor settings are largely combinations of two nucleoside RTIs and a non-nucleoside RTI or PI. The effectiveness of these combinations decreases over time, requiring a switch to combinations that retain potency in the presence of viral resistance. Increasing access to second-line FDCs and new developments in first-line ARV therapy are cost challenges. In high-income countries the cost of ARV therapy is largely irrelevant, except for advanced salvage drugs such as enfuvirtide. In resource-poor settings cost is a huge factor that limits drug access, resulting in high rates of new infection and subsequent mortality. IP coverage, where granted, can keep access prices for essential ARVs higher than would otherwise be the case. Large, innovator companies have made drugs available at prices very close to the cost of manufacturing for lowest income countries. Generic providers in India and elsewhere provide the largest supply of drugs for the developing world. The recent issuance of Voluntary and Compulsory Licenses (VLs, CLs) through the World Trade Organization's TRIP (Treaty Respecting Intellectual Property) provisions arguably contribute to bringing down access prices. The utilization of improved science, pooled purchasing and intelligent procurement practices all definitely contribute to access. This work surveys the production processes for several critical ARVs. These are discussed in terms of scale up, raw material/intermediates and active pharmaceutical ingredient (API) costs. In some cases new routes to APIs or critical intermediates are needed. Based on potential new chemistries, there are significant opportunities to reduce cost for a number of critical ARVs." @default.
• W2041820493 created "2016-06-24" @default.
• W2041820493 creator A5013409006 @default.
• W2041820493 creator A5044492580 @default.
• W2041820493 creator A5053725340 @default.
• W2041820493 date "2008-09-01" @default.
• W2041820493 modified "2023-10-13" @default.
• W2041820493 title "A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations" @default.
• W2041820493 cites W124544113 @default.
• W2041820493 cites W1506669191 @default.
• W2041820493 cites W1928944685 @default.
• W2041820493 cites W1965162861 @default.
• W2041820493 cites W1965423838 @default.
• W2041820493 cites W1965547535 @default.
• W2041820493 cites W1965685475 @default.
• W2041820493 cites W1966966643 @default.
• W2041820493 cites W1968249260 @default.
• W2041820493 cites W1970381834 @default.
• W2041820493 cites W1976054636 @default.
• W2041820493 cites W1977582223 @default.
• W2041820493 cites W1978230205 @default.
• W2041820493 cites W1978563341 @default.
• W2041820493 cites W1979287116 @default.
• W2041820493 cites W1980990875 @default.
• W2041820493 cites W1981444630 @default.
• W2041820493 cites W1982101937 @default.
• W2041820493 cites W1983357954 @default.
• W2041820493 cites W1983472647 @default.
• W2041820493 cites W1983476601 @default.
• W2041820493 cites W1985257364 @default.
• W2041820493 cites W1985553517 @default.
• W2041820493 cites W1985622714 @default.
• W2041820493 cites W1987573971 @default.
• W2041820493 cites W1988079295 @default.
• W2041820493 cites W1992534470 @default.
• W2041820493 cites W1992921405 @default.
• W2041820493 cites W1992941323 @default.
• W2041820493 cites W1997308213 @default.
• W2041820493 cites W1997671905 @default.
• W2041820493 cites W1999948429 @default.
• W2041820493 cites W2002012046 @default.
• W2041820493 cites W2002722462 @default.
• W2041820493 cites W2008670195 @default.
• W2041820493 cites W2009372668 @default.
• W2041820493 cites W2010703635 @default.
• W2041820493 cites W2011108628 @default.
• W2041820493 cites W2012233557 @default.
• W2041820493 cites W2012721536 @default.
• W2041820493 cites W2012728569 @default.
• W2041820493 cites W2013416590 @default.
• W2041820493 cites W2014327917 @default.
• W2041820493 cites W2014744174 @default.
• W2041820493 cites W2016460330 @default.
• W2041820493 cites W2018681592 @default.
• W2041820493 cites W2020999490 @default.
• W2041820493 cites W2021968949 @default.
• W2041820493 cites W2022943380 @default.
• W2041820493 cites W2030375335 @default.
• W2041820493 cites W2032102338 @default.
• W2041820493 cites W203617234 @default.
• W2041820493 cites W2038810478 @default.
• W2041820493 cites W2039599638 @default.
• W2041820493 cites W2046348452 @default.
• W2041820493 cites W2048215733 @default.
• W2041820493 cites W2049413619 @default.
• W2041820493 cites W2049491331 @default.
• W2041820493 cites W2049821854 @default.
• W2041820493 cites W2050747066 @default.
• W2041820493 cites W2055806371 @default.
• W2041820493 cites W2056801405 @default.
• W2041820493 cites W2061051850 @default.
• W2041820493 cites W2062166303 @default.
• W2041820493 cites W2062795681 @default.
• W2041820493 cites W2067582620 @default.
• W2041820493 cites W2068687016 @default.
• W2041820493 cites W2070690611 @default.
• W2041820493 cites W2077679375 @default.
• W2041820493 cites W2082622136 @default.
• W2041820493 cites W2082683613 @default.
• W2041820493 cites W2087637851 @default.
• W2041820493 cites W2087710304 @default.
• W2041820493 cites W2089127100 @default.
• W2041820493 cites W2089659832 @default.
• W2041820493 cites W2093646780 @default.
• W2041820493 cites W2093827769 @default.
• W2041820493 cites W2094040927 @default.
• W2041820493 cites W2096099963 @default.
• W2041820493 cites W2096777825 @default.
• W2041820493 cites W2096887401 @default.
• W2041820493 cites W2101818517 @default.
• W2041820493 cites W2102277076 @default.
• W2041820493 cites W2105175831 @default.
• W2041820493 cites W2106437096 @default.
• W2041820493 cites W2113644342 @default.
• W2041820493 cites W2116358656 @default.
• W2041820493 cites W2117784959 @default.
• W2041820493 cites W2125680824 @default.
• W2041820493 cites W2127137755 @default.

• next